A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Interventions

DRUG

SHR-1819 injection

SHR-1819 injection.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of China Medical University, Shenyang

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY